
Downloaded from: http://researchonline.lshtm.ac.uk/9710/

DOI: 10.1136/bmj.39136.475313.FA

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Letters

SPENDING ON HIV

HIV funding: debate misses the point

As one who has lost five out of 11 siblings to HIV, I cannot but be aware of the magnitude of HIV. Though the figures of England and de Lay et al differ,1,2 the element of relative overspending on HIV compared with other health and social developmental sectors is obvious.

Both miss the crucial point that HIV is the only tropical disease receiving anywhere near Western rates of health funding. The reasons for this include the global nature of HIV, the wages and expenses of expatriate health workers, and the many groups working with HIV in the tropics. England could have argued that the money channelled into HIV should be spent through local national health departments. Some African non-governmental organisations and de Lay et al may argue for the status quo, which has created, in some cases to the detriment of health and governance institutions, parallel institutions as it benefits their causes. England should have presented a breakdown of how the HIV funding is being used. He may find that only a small fraction trickles down to African patients with HIV and that a significant chunk bounces back to the West.3

John Lwanda, medical practitioner, Rutherglen, Glasgow G73 5HN lwanda2000@yahoo.co.uk

Competing interests: None declared.


PANDEMIC FLU

Look at all the evidence before stockpiling amantadine

Tsiodras et al propose testing amantadine to see if any benefits could accrue in combination with neuraminidase inhibitors in pandemic flu.1 The principal attraction seems to be low cost. Although they quote resistance and harms as well as lack of “any demonstrable reduction in transmissibility or pathogenicity,” this does not seem to deter them from their proposal.

Had they consulted the Cochrane Library, they would have discovered that amantadine (the only adamantane for which we have a reasonable knowledge base) relieves or suppresses symptoms if taken within 48 h, but it does not prevent infection with influenza A viruses or stop their nasal excretion. This is the key finding in a pandemic as apparently healthy individuals devoid of symptoms and feeling good because they have taken “the pill” would be spreading influenza viruses in the community through contact and droplets. Amantadine suppresses symptoms but not infection, it does not prevent or even diminish the risk of influenza communication, it causes unacceptable harms, resistance to it is widespread and swiftly induced: it is a very dangerous drug, especially in a pandemic.2

Would the authors give prophylactic amantadine to essential workers knowing it causes gastrointestinal symptoms (mainly nausea, odds ratio 2.56; 95% confidence interval 1.37 to 4.79) and insomnia and hallucinations (2.54; 1.50 to 4.31) and caused withdrawals from the trials because of adverse events (2.54; 1.60 to 4.06)?2 Would they give it to ambulance drivers, train conductors, and helicopter pilots?

If pharmacological intervention is required to help contain a pandemic, then neuraminidase inhibitors are far safer and more effective than adamantanes.3 No benefit, but a lot of harm will accrue with continued use of amantadine. That is what all available comparative evidence shows.

Tom Jefferson. Cochrane Acute Respiratory Infections Group, Anguilla Sabazia, Rome 00061, Italy jefferson.tom@gmail.com

Competing interests: TJ is the first author of both relevant Cochrane reviews. He holds no stock or shares and has not received any fees in the past five years from any organisation which could benefit or be harmed by this letter.

1 Tsiodras S, Mooney JD, Hatzakis A. Role of combination antiviral therapy in pandemic influenza and stockpiling implications. BMJ 2007;334:393-4. (10 February.)
WHO FUNDING

World Health Organization refutes allegations

The World Health Organization categorically rejects the allegations made in a recent story in the BMJ which imply that WHO solicits money from the pharmaceutical sector through independent organisations by circumventing its own rules.1

As the BMJ correctly reports, WHO has clear guidelines against seeking or accepting funds from commercial enterprises or through third parties where there would be a conflict of interest.

When WHO does accept donations or funds from pharmaceutical companies—for example, donations of vaccines or medicines—those donations are clearly accounted for and transparently reported.

In this specific case, Dr Benedetto Saraceno was very clear. He had never asked that funds be solicited from the pharmaceutical sector, and he declined the funds that were offered.

WHO is concerned about the BMJ’s depiction of Dr Saraceno. He is a professional of deep personal integrity. In the 10 years he has been with WHO, Dr Saraceno has tirelessly worked to highlight the public health consequences and grave inequalities faced by the millions of people who are affected by mental, neurological, or behavioural disorders.

Christine McNab, acting director of communications, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland mcnab@who.int

Competing interests: None declared.


RANDOMISED TRIALS

The urge to sprinkle statistics is irresistible

We might be forgiven for believing that Glasziou et al had discovered some hitherto unknown method of causal inference.1 Instead they have merely stumbled across the way in which causes have been identified in everyday life and science throughout history.2

The “mother’s kiss” technique for removing a bead lodged in a nostril is an effective treatment not only because it has been shown to work in case reports but also because it is grounded in elementary principles of physics familiar to every child who has played with a pea shooter. It does not need statistical analysis. Yet, the authors—unable to free themselves of the urge to season the data with a sprinkle of relative risks or P-values—neglect the fact that the many examples they provide of treatments with clearly observable effects are widely accepted without the need for statistical tricks.

The obsession with both randomised controlled trials and the statistical approach to causation has clouded the thinking of a generation or more of medical researchers.

So much so, that the commonsense notion of causation has been relegated to little more than an afterthought. And this accounts for the dismissive approach to any data not derived from randomised trials.

Perhaps, after their damascene conversion, Glasziou et al will campaign for a change in the hierarchy of evidence in favour of data from non-randomised sources.

James Penston, consultant physician, Scunthorpe General Hospital, Scunthorpe, North Lincolnshire DN15 7BH james.penston@nig.nhs.uk

Competing interests: None declared.


Beware “Texas sharp shooter” in rate ratios of progression

Glasziou et al’s method of calculating rate ratios of progression (stable unchanging condition before v change shortly after the intervention) is appealing,1 but we need to be wary of a “Texas sharp shooter” effect. This effect is usually associated in epidemiology with the problem of interpreting apparent clusters of disease in space, where the geographical unit of analysis may have been chosen post hoc so as to maximise the apparent density of cases as in the joke about a Texan firing bullets into the wall of a barn and then drawing the targets around the bullet holes to show his shooting prowess.

An analogous problem may occur when calculating rate ratios in the manner described in this article, although the sharp shooting is in time, not space. In the mother’s kiss, the time period used is 10s, which gives a rate ratio of progression of 1440. Perhaps, however, the bead dislodged after only 8s, a rate ratio of 1440/0.8=1800. Alternatively, if the bead had taken 15s to dislodge, the doctor, nurse, and mother might still reasonably have felt that they should take the credit for the happy outcome. You need to make an a priori decision about the post intervention time frame you will use—presumably based on the maximum length of time after the event you are prepared to attribute any improvement to your intervention.

Anna C Goodman, PhD student, London School of Hygiene and Tropical Medicine, London WC1E 7HT anna.goodman@lshtm.ac.uk

Competing interests: None declared.


MORPHINE

Double effect is a myth leading a double life

Kelly Taylor’s request to use morphine “to make her unconscious” under the principle of double effect is a puzzling choice.1

Evidence over the past 20 years has repeatedly shown that, used correctly, morphine is well tolerated and does not shorten life or hasten death.2 Its sedative effects wear off quickly, toxic doses can cause distressing agitation, and it has a wide therapeutic range. The Dutch know this and hardly ever use morphine for euthanasia.3

Palliative care specialists are not faced with the dilemma of controlling severe pain at the risk of killing the patient: they manage pain with drugs and doses adjusted to each patient, while at the same time helping fear, depression, and spiritual distress. Doctors who act precipitously with high, often intravenous, doses of opioids may do so out of compassionate panic, but they are being misled into bad practice by the continuing promotion of double effect as a real and essential phenomenon in end of life care. Using double effect as a justification for patient assisted suicide and euthanasia on the grounds that it is already being done under the rubric of double effect is not tenable in evidence based medicine.4

In end of life care double effect is a myth leading a double life.

Clau de Regnard, consultant in palliative care medicine, St Oswald's Hospice, Newcastle upon Tyne NE3 1EE clauderegnard@stoswaldsuk.org

Competing interests: None declared.

1 Dyer C. Dying woman seeks backing to hasten death. BMJ 2007;334:329. (17 February.)

